Tarsus Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Janus Henderson Group Ltd. has amended its Schedule 13G filing, reporting a decrease in its beneficial ownership of Tarsus Pharmaceuticals, Inc. common stock to 6.5%.
NASDAQ
Janus Henderson Group plc has reported a beneficial ownership of 5.3% in Tarsus Pharmaceuticals, Inc., holding 2,240,963 shares as of March 31, 2026.
NASDAQ
Deep Track Capital, LP, along with its affiliates, has reported beneficial ownership of 3,600,000 shares, representing 8.46% of the outstanding common stock of Tarsus Pharmaceuticals, Inc. as of March 31, 2026.
NASDAQ
Prudential Financial, Inc. disclosed a reduction in its beneficial ownership of Tarsus Pharmaceuticals, Inc. common stock to 4.3%.
NASDAQ
Jennison Associates LLC has reported a 4.0% beneficial ownership of Tarsus Pharmaceuticals Inc. common stock as of March 31, 2026.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Tarsus Pharmaceuticals Inc. following an internal realignment.
NASDAQ
Deep Track Capital, LP and its affiliates have filed an amended Schedule 13G, reporting a continued beneficial ownership of 7.11% in Tarsus Pharmaceuticals, Inc.
NASDAQ
RTW Investments, LP and Roderick Wong, M.D. have reported a beneficial ownership of 8.1% in Tarsus Pharmaceuticals, Inc.
NASDAQ
Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a beneficial ownership of 5.6% in Tarsus Pharmaceuticals, Inc.'s common stock.
NASDAQ
SCHEDULE 13G/A: Tang Capital Group Maintains 5.9% Stake in Tarsus Pharmaceuticals, Files Amended Schedule 13G
Tang Capital Management, LLC and its affiliated entities, including Kevin Tang, have filed an amended Schedule 13G, reaffirming their collective beneficial ownership of 5.90% of Tarsus Pharmaceuticals, Inc.'s common stock as of March 31, 2025.
NASDAQ
Morgan Stanley has filed an amended Schedule 13G, indicating it has ceased to be a beneficial owner of more than five percent of Tarsus Pharmaceuticals, Inc.'s common stock as of March 31, 2025.
NASDAQ
BlackRock, Inc. has filed an updated Schedule 13G, disclosing a 7.4% beneficial ownership stake in Tarsus Pharmaceuticals, Inc. as of March 31, 2025.
NASDAQ
Cowen Financial Products LLC has reported a 4.9% beneficial ownership stake in Tarsus Pharmaceuticals Inc. as of December 31, 2024, according to its latest Schedule 13G filing.